Y0001510
Lactulose for peak identification
European Pharmacopoeia (EP) Reference Standard
别名:
Lactulose, 4-O-β-D-Galactopyranosyl-D-fructofuranose, 4-O-β-D-Galactopyranosyl-D-fructose
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C12H22O11
CAS号:
分子量:
342.30
Beilstein:
93773
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
推荐产品
等级
pharmaceutical primary standard
API类
lactulose
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
OC[C@H]1O[C@@H](O[C@@H]2[C@@H](CO)O[C@@](O)(CO)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O
InChI
1S/C12H22O11/c13-1-4-6(16)7(17)8(18)11(21-4)22-9-5(2-14)23-12(20,3-15)10(9)19/h4-11,13-20H,1-3H2/t4-,5-,6+,7+,8-,9-,10+,11+,12+/m1/s1
InChI key
JCQLYHFGKNRPGE-WJONTELPSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Lactulose for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
储存分类代码
11 - Combustible Solids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
Parmjit S Panesar et al.
Biotechnology advances, 29(6), 940-948 (2011-08-23)
Lactulose a "bifidus factor" is composed of galactose and fructose, which can be produced by the isomerization of lactose. It is a prebiotic carbohydrate which stimulates the growth of health-promoting bacteria in the gastrointestinal tract, such as bifidobacteria and lactobacilli
Srinivasan Dasarathy
Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 22 Suppl 2, S50-S53 (2004-03-18)
The pathogenesis of hepatic encephalopathy is mediated to a large extent by ammonia, mainly derived from the gut. Both bacterial and nonbacterial mechanisms of ammoniagenesis have been shown, but ammoniagenesis mediated by colonic bacteria is probably of clinical significance. The
Heather Lee-Robichaud et al.
The Cochrane database of systematic reviews, (7)(7), CD007570-CD007570 (2010-07-09)
Constipation is a common clinical problem. Lactulose and Polyethylene Glycol (PEG) are both commonly used osmotic laxatives that have been shown to be effective and safe treatments for chronic constipation. However, there is no definitive data as to which provides
Rifaximin for episodic, overt hepatic encephalopathy: the data are catching up to clinical practice, but questions remain.
Stephen E Congly et al.
The American journal of gastroenterology, 109(4), 598-598 (2014-04-05)
F L Weber
Digestive diseases (Basel, Switzerland), 14 Suppl 1, 53-63 (1996-01-01)
Lactulose is the most frequently utilized agent in the treatment of hepatic encephalopathy because of its efficacy and the fact that it has few serious side effects. How this nonabsorbable disaccharide works has been a matter of controversy, but evidence
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门